COMBINATION THERAPIES FOR TREATMENT OF HER2 CANCER
Provided are combination therapies comprising inavolisib (a.k.a. GDC-0077) and other HER2-targeted therapies (e.g., pertuzumab and trastuzumab) for the treatment of HER2-positive cancers; and methods of treating HER2 positive (HER2+) cancers in a patient (preferably a patient with a PIK3CA mutant br...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | SONG, KYUNG WHA JOO, STEPHANIE ROYER THANOPOULOU, EIRINI SCHUTZMAN, JENNIFER LEE SONG, CHUNYAN WARBURTON, SIMON PETER DEY, ANWESHA |
| description | Provided are combination therapies comprising inavolisib (a.k.a. GDC-0077) and other HER2-targeted therapies (e.g., pertuzumab and trastuzumab) for the treatment of HER2-positive cancers; and methods of treating HER2 positive (HER2+) cancers in a patient (preferably a patient with a PIK3CA mutant breast cancer) comprising administering a therapeutically effective amount of inavolisib and a HER2-targeted therapy (e.g., trastuzumab, pertuzumab, or a combination of trastuzumab and pertuzumab).
L'invention concerne des polythérapies comprenant de l'inavolisib (alias GDC-0077) et d'autres thérapies ciblant HER2 (par exemple, le pertuzumab et le trastuzumab) pour le traitement de cancers HER2-positifs ; et des méthodes de traitement de cancers positifs à HER2 (HER2+) de cancers chez un patient (de préférence un patient atteint d'un cancer du sein mutant PIK3CA) comprenant l'administration d'une quantité thérapeutiquement efficace d'inavolisib et d'une thérapie ciblant HER2 (par exemple, le trastuzumab, le pertuzumab, ou une combinaison de trastuzumab et de pertuzumab). |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CA3204489A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CA3204489A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CA3204489A13</originalsourceid><addsrcrecordid>eNrjZDBy9vd18vRzDPH091MI8XANcgzwdA1WcPMPUggJcnUM8XX1C1Hwd1MAyhgpODv6ObsG8TCwpiXmFKfyQmluBgU31xBnD93Ugvz41OKCxOTUvNSSeGdHYyMDExMLS0dDYyKUAAAc5SYg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>COMBINATION THERAPIES FOR TREATMENT OF HER2 CANCER</title><source>esp@cenet</source><creator>SONG, KYUNG WHA ; JOO, STEPHANIE ROYER ; THANOPOULOU, EIRINI ; SCHUTZMAN, JENNIFER LEE ; SONG, CHUNYAN ; WARBURTON, SIMON PETER ; DEY, ANWESHA</creator><creatorcontrib>SONG, KYUNG WHA ; JOO, STEPHANIE ROYER ; THANOPOULOU, EIRINI ; SCHUTZMAN, JENNIFER LEE ; SONG, CHUNYAN ; WARBURTON, SIMON PETER ; DEY, ANWESHA</creatorcontrib><description>Provided are combination therapies comprising inavolisib (a.k.a. GDC-0077) and other HER2-targeted therapies (e.g., pertuzumab and trastuzumab) for the treatment of HER2-positive cancers; and methods of treating HER2 positive (HER2+) cancers in a patient (preferably a patient with a PIK3CA mutant breast cancer) comprising administering a therapeutically effective amount of inavolisib and a HER2-targeted therapy (e.g., trastuzumab, pertuzumab, or a combination of trastuzumab and pertuzumab).
L'invention concerne des polythérapies comprenant de l'inavolisib (alias GDC-0077) et d'autres thérapies ciblant HER2 (par exemple, le pertuzumab et le trastuzumab) pour le traitement de cancers HER2-positifs ; et des méthodes de traitement de cancers positifs à HER2 (HER2+) de cancers chez un patient (de préférence un patient atteint d'un cancer du sein mutant PIK3CA) comprenant l'administration d'une quantité thérapeutiquement efficace d'inavolisib et d'une thérapie ciblant HER2 (par exemple, le trastuzumab, le pertuzumab, ou une combinaison de trastuzumab et de pertuzumab).</description><language>eng ; fre</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220616&DB=EPODOC&CC=CA&NR=3204489A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76516</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220616&DB=EPODOC&CC=CA&NR=3204489A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>SONG, KYUNG WHA</creatorcontrib><creatorcontrib>JOO, STEPHANIE ROYER</creatorcontrib><creatorcontrib>THANOPOULOU, EIRINI</creatorcontrib><creatorcontrib>SCHUTZMAN, JENNIFER LEE</creatorcontrib><creatorcontrib>SONG, CHUNYAN</creatorcontrib><creatorcontrib>WARBURTON, SIMON PETER</creatorcontrib><creatorcontrib>DEY, ANWESHA</creatorcontrib><title>COMBINATION THERAPIES FOR TREATMENT OF HER2 CANCER</title><description>Provided are combination therapies comprising inavolisib (a.k.a. GDC-0077) and other HER2-targeted therapies (e.g., pertuzumab and trastuzumab) for the treatment of HER2-positive cancers; and methods of treating HER2 positive (HER2+) cancers in a patient (preferably a patient with a PIK3CA mutant breast cancer) comprising administering a therapeutically effective amount of inavolisib and a HER2-targeted therapy (e.g., trastuzumab, pertuzumab, or a combination of trastuzumab and pertuzumab).
L'invention concerne des polythérapies comprenant de l'inavolisib (alias GDC-0077) et d'autres thérapies ciblant HER2 (par exemple, le pertuzumab et le trastuzumab) pour le traitement de cancers HER2-positifs ; et des méthodes de traitement de cancers positifs à HER2 (HER2+) de cancers chez un patient (de préférence un patient atteint d'un cancer du sein mutant PIK3CA) comprenant l'administration d'une quantité thérapeutiquement efficace d'inavolisib et d'une thérapie ciblant HER2 (par exemple, le trastuzumab, le pertuzumab, ou une combinaison de trastuzumab et de pertuzumab).</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDBy9vd18vRzDPH091MI8XANcgzwdA1WcPMPUggJcnUM8XX1C1Hwd1MAyhgpODv6ObsG8TCwpiXmFKfyQmluBgU31xBnD93Ugvz41OKCxOTUvNSSeGdHYyMDExMLS0dDYyKUAAAc5SYg</recordid><startdate>20220616</startdate><enddate>20220616</enddate><creator>SONG, KYUNG WHA</creator><creator>JOO, STEPHANIE ROYER</creator><creator>THANOPOULOU, EIRINI</creator><creator>SCHUTZMAN, JENNIFER LEE</creator><creator>SONG, CHUNYAN</creator><creator>WARBURTON, SIMON PETER</creator><creator>DEY, ANWESHA</creator><scope>EVB</scope></search><sort><creationdate>20220616</creationdate><title>COMBINATION THERAPIES FOR TREATMENT OF HER2 CANCER</title><author>SONG, KYUNG WHA ; JOO, STEPHANIE ROYER ; THANOPOULOU, EIRINI ; SCHUTZMAN, JENNIFER LEE ; SONG, CHUNYAN ; WARBURTON, SIMON PETER ; DEY, ANWESHA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CA3204489A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2022</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>SONG, KYUNG WHA</creatorcontrib><creatorcontrib>JOO, STEPHANIE ROYER</creatorcontrib><creatorcontrib>THANOPOULOU, EIRINI</creatorcontrib><creatorcontrib>SCHUTZMAN, JENNIFER LEE</creatorcontrib><creatorcontrib>SONG, CHUNYAN</creatorcontrib><creatorcontrib>WARBURTON, SIMON PETER</creatorcontrib><creatorcontrib>DEY, ANWESHA</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>SONG, KYUNG WHA</au><au>JOO, STEPHANIE ROYER</au><au>THANOPOULOU, EIRINI</au><au>SCHUTZMAN, JENNIFER LEE</au><au>SONG, CHUNYAN</au><au>WARBURTON, SIMON PETER</au><au>DEY, ANWESHA</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>COMBINATION THERAPIES FOR TREATMENT OF HER2 CANCER</title><date>2022-06-16</date><risdate>2022</risdate><abstract>Provided are combination therapies comprising inavolisib (a.k.a. GDC-0077) and other HER2-targeted therapies (e.g., pertuzumab and trastuzumab) for the treatment of HER2-positive cancers; and methods of treating HER2 positive (HER2+) cancers in a patient (preferably a patient with a PIK3CA mutant breast cancer) comprising administering a therapeutically effective amount of inavolisib and a HER2-targeted therapy (e.g., trastuzumab, pertuzumab, or a combination of trastuzumab and pertuzumab).
L'invention concerne des polythérapies comprenant de l'inavolisib (alias GDC-0077) et d'autres thérapies ciblant HER2 (par exemple, le pertuzumab et le trastuzumab) pour le traitement de cancers HER2-positifs ; et des méthodes de traitement de cancers positifs à HER2 (HER2+) de cancers chez un patient (de préférence un patient atteint d'un cancer du sein mutant PIK3CA) comprenant l'administration d'une quantité thérapeutiquement efficace d'inavolisib et d'une thérapie ciblant HER2 (par exemple, le trastuzumab, le pertuzumab, ou une combinaison de trastuzumab et de pertuzumab).</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_CA3204489A1 |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | COMBINATION THERAPIES FOR TREATMENT OF HER2 CANCER |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T13%3A47%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=SONG,%20KYUNG%20WHA&rft.date=2022-06-16&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECA3204489A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |